解脲脲原体喹诺酮类药物耐药机制的研究  

To study of resistance mechanisms of Ureaplasma urealyticum to quinolones

作　　者：张一沙[1] 吴颖[2] 范兴丽[3] 蒋锦琴[3] 孙爱华[3] 

机构地区：[1]浙江省台州市中西医结合医院泌尿外科,浙江温岭317523 [2]浙江省台州市中西医结合医院检验科,浙江温岭317523 [3]浙江医学高等专科学校基础医学部,浙江杭州31005

出　　处：《中国现代医生》2012年第16期1-3,共3页China Modern Doctor

基　　金：浙江省医药卫生科学研究基金项目计划(2004A018)

摘　　要：目的研究解脲脲原体喹诺酮类药物耐药机制。方法用支原体培养、鉴定和药敏试剂盒分离获得77株解脲脲原体并检测对3种喹诺酮类药物的耐药性,同时PCR法扩增临床分离株的gyrA和parC基因喹诺酮耐药决定区并进行测序分析。结果对3种喹诺酮均敏感3株,74株至少对1种药物呈现不同程度耐药。gyrA和parC基因喹诺酮耐药决定区测序发现上述敏感株和2株耐药株不发生突变,其余72株耐药株gyrA和parC发生D112E和/或S83L突变。结论解脲脲原体gyrA和parC基因喹诺酮耐药决定区突变与耐药密切相关。Objective To study the resistance mechanisms of Ureaplasma urealyticum to quinolones. Methods Mycoplasma detection kits were used to culture and identify mycoplasma as well as drug sensitivity. PCR and DNA sequencing were conducted to analyze QRDR associated genes of gyrA and parC in 77 isolates. Results There were only 3 isolates susceptible to all quinolones, and 74 isolates showed varying degree resistance to at least one kind of quinolone. Sequencing analysis of gyrA and parC revealed that 3 susceptible isolates and 2 resistant isolates had no mutation, 72 resistant isolates had muta- tion of D112E and/or S83L in gyrA and parC. Conclusion Mutations in gyrA and parC genes play an important role in the development of quinolones resistance in Ureaplasma urealyticum.

关 键 词：解脲脲原体 GYRA PARC基因 突变 序列分析 耐药性 

分 类 号：R446.5[医药卫生—诊断学]